|
PEPFAR Implementation Science Network
|
Research Initiative
|
CDC
|
OD/DPCPSI/ORWH, FIC, NICHD, NIMH
|
2010 WHO recommendations to provide antiretroviral prophylaxis or treatment to mothers or infants during the breastfeeding period have not been adopted in resource poor countries. The goal of this study is to evaluate the effect of a "feeding buddy" to support mothers to adhere to prevention of mother to child HIV transmission. This is a prospective cohort intervention study set within a comprehensive ongoing national program addressing maternal and child health.
|
|
Pertussis Working Group
|
Other
|
CDC, FDA
|
NIAID
|
The objective of the Pertussis Working Group is to share information and promote collaborations among HHS agencies in order to better understand the recent resurgence of pertussis in the United States and identify potential strategies to address the problem.
|
|
Phenylketonuria (PKU) and Pregnancy
|
Meeting/ Workshop
|
AHRQ
|
NICHD
|
Phenylketonuria (PKU) is a disorder of metabolism that can cause intellectual and developmental disabilities (IDD) if not treated. In PKU, the body cannot process the amino acid, phenylalanine (Phe), a component of the proteins found in foods. If the Phe level gets too high, the brain can become damaged. For nearly 50 years, newborn screening programs have successfully identified infants with PKU within days of birth, allowing treatment via dietary protein restriction to begin almost immediately, thereby preventing IDD. In October 2000, the NIH published a Consensus Development Conference Statement on the screening and management of PKU. Since then, new treatments and medications have emerged. To assist clinicians in making treatment decisions, NIH has revisited the 2000 guidelines. Five working groups composed of 8–12 topical experts, public members, and federal stakeholders were convened to explore the expanded body of literature and address important questions regarding treatment of PKU. The working groups were organized around the following topics: Diet Control and Management Pharmacologic Interventions PKU and Pregnancy Long-Term Outcomes and Management across the Lifespan Molecular Testing, New Technologies, and Epidemiologic Considerations These working groups presented their findings during this conference. In a parallel and collaborative effort, an Evidence-based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ) has conducted an evidence-based review of the comparative effectiveness of treatment for PKU, including diet and sapropterin dihydrochloride. Together, the PKU Scientific Review Conference and the AHRQ EPC report will examine evidence on important issues related to management of PKU. Public input will be solicited and a final document will be published. This conference will consider the state of the science, recent research findings, current treatments, and future research needs related to PKU.
|
|
Phenylketonuria (PKU) Scientific Workshop
|
Meeting/ Workshop
|
AHRQ, FDA, HRSA
|
NCATS, NHGRI, NICHD, NIDDK, NINDS, NINR
|
In October 2000, the NIH published a Consensus Development Conference Statement for screening and management of PKU. Since then, new treatments, including pharmacological, have emerged. To assist clinicians in making treatment decisions, NIH has revisited the guidelines. Five working groups were convened to explore an expanded body of literature and address important questions regarding treatment of PKU. These working groups will present their findings during the conference on February 22-23, 2012.
|
|
PHS MSM Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI
|
The working group is developing guidelines and strategies to improve HIV/STD programs for men who have sex with men (MSM).
|
|
Physical Activity and Disease Prevention: Identifying Research Priorities
|
Meeting/ Workshop
|
AHRQ, CDC, OS
|
OD/DPCPSI/ODP, NCI, NHLBI, NIA, NIBIB, NICHD, NIDA
|
This workshop was coordinated and funded by the National Institutes of Health (NIH) Office of Disease Prevention (ODP) to convene NIH and federal partners to examine: barriers to achieving the federal Physical Activity Guidelines, effective evidence-based interventions for initiating and sustaining physical activity, NIH’s physical activity research portfolio, and current and emerging research methodologies. The workshop focused on NIH’s interest in supporting innovative research to improve physical activity assessment and research methods used with diverse age and racial/ethnic populations as well as prioritizing the NIH physical activity research agenda. The meeting was held on December 13-14, 2012.
|
|
Pillbox
|
Resource Development
|
FDA
|
NLM
|
The National Library of Medicine and the Food and Drug Administration have established a collaborative relationship to enhance patient safety through the linking of digital images of prescription solid dosage form medications to the Structured Product Labeling (SPL) files and the substance information of those pharmaceuticals.
|
|
Pink Ribbon Red Ribbon (PRRR)
|
Meeting/ Workshop
|
CDC
|
NCI
|
The Pink Ribbon Red Ribbon (PRRR) is a partnership to leverage public and private sector investments to address breast and cervical cancers in developing countries. It is being implemented in several countries in sub-Saharan Africa. NCI and CDC provide technical assistance in implementation strategies to the PRRR countries. This assistance involves drafting guidelines for monitoring and evaluation of prevention and treatment services as well as developing communication strategies.
|
|
Playful Learning Group
|
Other
|
ACF
|
NICHD
|
Collaboration to improve learning in children.
|
|
Pluripotent Stem Cells in Translation: Early Decisions
|
Meeting/ Workshop
|
FDA
|
NINDS, NHLBI, NIDCR, OD/DPCPSI
|
The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are organizing a series of workshops that will engage the broader research community regarding requirements necessary for translation of pluripotent stem cell-derived products into the clinic. The first workshop, held March 2011, focused on establishment of stem cell lines and banks, covering safety and regulatory issues related to how the original cell line derivation is done in the case of embryonic stem cells, and how the cells are reprogrammed in the case of iPS cells. The second workshop, held July 10-11, 2012, focused on preclinical safety and proof of concept testing, including, among other topics, clinical relevance of the animal models, selection of cell dose levels, impact of host microenvironment, and cell fate post-administration. A third, and final, workshop is expected to focus on clinical trial design including safety monitoring, immunogenicity, immunosuppressant use and immune monitoring.
|